Evaluation of ERG responsive proteome in prostate cancer

Prostate

Volumn 74, Issue 1, 2014, Pages 70-89

  Tan, Shyh Han ^a   Furusato, Bungo ^a   Fang, Xueping ^b   He, Fang ^b   Mohamed, Ahmed A ^a   Griner, Nicholas B ^a   Sood, Kaneeka ^a   Saxena, Sadhvi ^a   Katta, Shilpa ^a   Young, Denise ^a   Chen, Yongmei ^a   Sreenath, Taduru ^a   Petrovics, Gyorgy ^a   Dobi, Albert ^a   McLeod, David G ^a   Sesterhenn, Isabell A ^c   Saxena, Satya ^b   Srivastava, Shiv ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b Calibrant Biosystemsm Inc   (United States)

^c JOINT PATHOLOGY CENTER   (United States)

Author keywords

actin and cytoskeletal reorganization; ERG; MAOA; myosin VI; proteomics

Indexed keywords

ACTIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BIOLOGICAL MARKER; MYOSIN VI; ONCOPROTEIN; PROTEASOME; PROTEOME; SMALL INTERFERING RNA; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CELL MIGRATION; CELL STRAIN LNCAP; CELL SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOSKELETON; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MALE; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ACTIN AND CYTOSKELETAL REORGANIZATION; ERG; MAOA; MYOSIN VI; PROTEOMICS;

AGED; CELL LINE, TUMOR; GENE REGULATORY NETWORKS; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEINS; PROSTATIC NEOPLASMS; PROTEOME; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890125967     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22731     Document Type: Article

References (55)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 (1): 11-30.
2. Dobi A, Sreenath T, Srivastava S,. Androgen-dependent oncogenic activation of ETS transcription factors by recurrent gene fusions in prostate cancer: Biological and clinical implications. In:, Wang Z, editor. Androgen-responsive genes in prostate cancer. New York: Springer, 2013. pp. 307-328.
3. Irshad S, Abate-Shen C,. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev 2013; 32 (1-2): 109-122.
4. Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, Luo J, Visakorpi T, Rubin MA,. The mutational landscape of prostate cancer. Eur Urol 2013; 64 (4): 567-576.
5. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, Nau M, Ravindranath L, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S,. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24 (23): 3847-3852.
6. Rubin MA, Maher CA, Chinnaiyan AM,. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29 (27): 3659-3668.
7. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648.
8. Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, Kudahetti SC, Stankiewicz E, Xue L, Beltran L, Gupta M, Oliver RT, Lemoine NR, Berney DM, Young BD, Lu YJ,. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 2010; 70 (13): 5207-5212.
9. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M,. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011; 71 (5): 489-497.
10. Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, Bohm D, Perner S, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S,. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 2012; 80 (4): 749-753.
11. Gasi Tandefelt D, Boormans JL, van der Korput HA, Jenster GW, Trapman J,. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. Eur Urol 2013; http://dx.doi.org/10.1016/j.eururo.2013.02.039 (In Press).
12. Massoner P, Kugler KG, Unterberger K, Kuner R, Mueller LA, Falth M, Schafer G, Seifarth C, Ecker S, Verdorfer I, Graber A, Sultmann H, Klocker H,. Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y. PLoS ONE 2013; 8 (2): e55207.
13. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG, Srivastava S,. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27 (40): 5348-5353.
14. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM,. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10 (2): 177-188.
15. Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, Chiorino G, Catapano CV, Carbone GM,. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS ONE 2010; 5 (5): e10547.
16. Sreenath T, Dobi A, Petrovics G, Srivastava S,. Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog 2011; 10: 37.
17. Cho JY, Lee M, Ahn JM, Park ES, Cho JH, Lee SJ, Kim BG, Heo SH, Park HJ, Zerbini LF, Hwang D, Libermann TA,. Proteomic analysis of a PDEF Ets transcription factor-interacting protein complex. J Proteome Res 2009; 8 (3): 1327-1337.
18. Drake RR, Elschenbroich S, Lopez-Perez O, Kim Y, Ignatchenko V, Ignatchenko A, Nyalwidhe JO, Basu G, Wilkins CE, Gjurich B, Lance RS, Semmes OJ, Medin JA, Kislinger T,. In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res 2010; 9 (5): 2109-2116.
19. Khan AP, Poisson LM, Bhat VB, Fermin D, Zhao R, Kalyana-Sundaram S, Michailidis G, Nesvizhskii AI, Omenn GS, Chinnaiyan AM, Sreekumar A,. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 2010; 9 (2): 298-312.
20. Sardana G, Jung K, Stephan C, Diamandis EP,. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008; 7 (8): 3329-3338.
21. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, Aebersold R, Nelson PS,. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004; 64 (1): 347-355.
22. Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, Cullen J, Furusato B, Chen Y, Thangapazham RL, Mohamed A, Sun C, Sesterhenn IA, McLeod DG, Petrovics G, Srivastava S,. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008; 14 (15): 4719-4725.
23. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA,. TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66 (17): 8337-8341.
24. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA,. ERG oncoprotein expression in prostate cancer: Clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13 (3): 228-237.
25. Johann DJ, Rodriguez-Canales J, Mukherjee S, Prieto DA, Hanson JC, Emmert-Buck M, Blonder J,. Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry. J Proteome Res 2009; 8 (5): 2310-2318.
26. Fang X, Wang W, Yang L, Chandrasekaran K, Kristian T, Balgley BM, Lee CS,. Application of capillary isotachophoresis-based multidimensional separations coupled with electrospray ionization-tandem mass spectrometry for characterization of mouse brain mitochondrial proteome. Electrophoresis 2008; 29 (10): 2215-2223.
27. Fang X, Yang L, Wang W, Song T, Lee CS, DeVoe DL, Balgley BM,. Comparison of electrokinetics-based multidimensional separations coupled with electrospray ionization-tandem mass spectrometry for characterization of human salivary proteins. Anal Chem 2007; 79 (15): 5785-5792.
28. Gu Y, Li H, Miki J, Kim KH, Furusato B, Sesterhenn IA, Chu WS, McLeod DG, Srivastava S, Ewing CM, Isaacs WB, Rhim JS,. Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res 2006; 312 (6): 831-843.
29. Mohamed AA, Tan SH, Sun C, Shaheduzzaman S, Hu Y, Petrovics G, Chen Y, Sesterhenn IA, Li H, Sreenath T, McLeod DG, Dobi A, Srivastava S,. ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther 2011; 11 (4): 410-417.
30. Smyth GK,. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
31. Oda K, Matsuoka Y, Funahashi A, Kitano H,. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; 1: 2005.0010.
32. Lin D, Edwards AS, Fawcett JP, Mbamalu G, Scott JD, Pawson T,. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat Cell Biol 2000; 2 (8): 540-547.
33. deLeon O, Puglise JM, Liu F, Smits J, ter Beest MB, Zegers MM,. Pak1 regulates the orientation of apical polarization and lumen formation by distinct pathways. PLoS ONE 2012; 7 (7): e41039.
34. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA, Andren O,. Molecular sampling of prostate cancer: A dilemma for predicting disease progression. BMC Med Genomics 2010; 3: 8.
35. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18 (1): 11-22.
36. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM, Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med 2012; 4 (127): 127rv123. http://stm.sciencemag.org.content/4/127/127rv3.full
37. Goo YA, Liu AY, Ryu S, Shaffer SA, Malmstrom L, Page L, Nguyen LT, Doneanu CE, Goodlett DR,. Identification of secreted glycoproteins of human prostate and bladder stromal cells by comparative quantitative proteomics. Prostate 2009; 69 (1): 49-461.
38. Hood BL, Malehorn DE, Conrads TP, Bigbee WL,. Serum proteomics using mass spectrometry. Methods Mol Biol 2009; 520: 107-128.
39. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Villette JM, Stower MJ, Maitland NJ,. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002; 52 (4): 253-263.
40. Grover PK, Resnick MI,. Analysis of prostatic fluid: Evidence for the presence of a prospective marker for prostatic cancer. Prostate 1995; 26 (1): 12-18.
41. Bitting RL, Armstrong AJ,. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 2013; 20 (3): R83-R99.
42. Grant S,. Cotargeting survival signaling pathways in cancer. J Clin Invest 2008; 118 (9): 3003-3006.
43. Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J,. A novel role of myosin VI in human prostate cancer. Am J Pathol 2006; 169 (5): 1843-1854.
44. Wei S, Dunn TA, Isaacs WB, De Marzo AM, Luo J,. GOLPH2 and MYO6: Putative prostate cancer markers localized to the Golgi apparatus. Prostate 2008; 68 (13): 1387-1395.
45. Puri C, Chibalina MV, Arden SD, Kruppa AJ, Kendrick-Jones J, Buss F,. Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis. Oncogene 2010; 29 (2): 188-200.
46. Tumbarello DA, Waxse BJ, Arden SD, Bright NA, Kendrick-Jones J, Buss F,. Autophagy receptors link myosin VI to autophagosomes to mediate Tom1-dependent autophagosome maturation and fusion with the lysosome. Nat Cell Biol 2012; 14 (10): 1024-1035.
47. Shih JC, Chen K, Ridd MJ,. Monoamine oxidase: From genes to behavior. Annu Rev Neurosci 1999; 22: 197-217.
48. Zhao H, Flamand V, Peehl DM,. Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics 2009; 2: 55.
49. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS,. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006; 103 (29): 10991-10996.
50. White TA, Kwon EM, Fu R, Lucas JM, Ostrander EA, Stanford JL, Nelson PS,. The monoamine oxidase A gene promoter repeat and prostate cancer risk. Prostate 2012; 72 (15): 1622-1627.
51. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE, Mills IG,. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007; 8 (9): 871-878.
52. Rahim S, Uren A,. Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. Am J Transl Res 2013; 5 (3): 254-268.
53. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM,. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19 (5): 664-678.
54. Heissler SM, Selvadurai J, Bond LM, Fedorov R, Kendrick-Jones J, Buss F, Manstein DJ,. Kinetic properties and small-molecule inhibition of human myosin-6. FEBS Lett 2012; 586 (19): 3208-3214.
55. Flamand V, Zhao H, Peehl DM,. Targeting monoamine oxidase A in advanced prostate cancer. J Cancer Res Clin Oncol 2010; 136 (11): 1761-1771.